Should You Buy Guided Therapeutics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Guided Therapeutics, Inc. (GTHP) presents a moderate quality profile with a QOC score of 5.5/10. Trading at $0.24, separating genuine undervalued opportunities from value traps is essential, as detailed by our model data.
The short answer: 0 of 1 CirclFi valuation models project upside for Guided Therapeutics, Inc. (GTHP) at $0.23 — the model consensus leans bearish, with a Quality Score of 5.5/10 and Value-Trap risk of 39/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Guided Therapeutics, Inc. (GTHP) in 2026?
What Is the Bull Case vs the Bear Case for Guided Therapeutics, Inc. (GTHP)?
| Bull case | Bear case — $0.01 target (-96.2%) |
|---|---|
| No active model projects meaningful upside for GTHP at $0.23. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | According to the CirclFi Quality of Company (QOC) framework, Guided Therapeutics, Inc.'s rating of 5.5/10 indicates below-average quality, raising questions about sustainable earnings levels. |
| According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $0.01 (-96.2%), suggesting that the market price embeds overly optimistic growth assumptions. | |
| Industry headwind: regulatory rejection risk represents a meaningful risk for Guided Therapeutics, Inc. and its Medical Devices peers. |
How Does GTHP Compare to Its Medical Devices Peers?
Valuation data pages: LUCD · INBS · NXL · QSI · PLSM · NUWE · LMRI · BRKR · TNDM · IRMD · PODD
Which Other Stocks Score Like GTHP on Quality?
Closest companies to GTHP’s Quality of Company score of 5.5/10, across all industries.
- LVWR — LiveWire Group, Inc. (QOC 5.5) · analysis
- CLIK — Click Holdings Limited (QOC 5.5) · analysis
- ZBAO — Zhibao Technology Inc. (QOC 5.5) · analysis
- SEED — Origin Agritech Limited (QOC 5.5) · analysis
- PWDY — Powerdyne International, Inc. (QOC 5.5) · analysis
- BOTY — Lingerie Fighting Championships, Inc. (QOC 5.5) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does GTHP Appear In?
So Is Guided Therapeutics, Inc. (GTHP) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Guided Therapeutics, Inc. at $0.24. 1/1 models flag overvaluation, median fair value sits at $0.01 (-96.2%), and the risk-reward profile appears unfavorable. Quality at 5.5/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Guided Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About GTHP Stock?
Should I buy GTHP stock right now?
Based on CirclFi's multi-model analysis, 0 of 1 models see upside for GTHP at $0.23. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Guided Therapeutics, Inc.?
Key risks include: limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does GTHP compare to its competitors?
Among Medical Devices peers, GTHP holds a Quality Score of 5.5/10. Comparable companies include LUCD (QOC 5.5), INBS (QOC 5.4), NXL (QOC 5.6). The relative ranking helps investors identify whether GTHP offers better fundamental quality than alternatives in the same sector.
Is GTHP a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. GTHP's Quality Score of 5.5/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy GTHP at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $0.01 to $0.01. At $0.23, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for GTHP.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad